^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CCR1 (C-C Motif Chemokine Receptor 1)

    i
    Other names: CCR1, C-C Motif Chemokine Receptor 1, MIP1aR, CMKBR1, SCYAR1, CKR-1, CD191, Macrophage Inflammatory Protein 1-Alpha Receptor, Chemokine (C-C Motif) Receptor 1, C-C Chemokine Receptor Type 1, LD78 Receptor, MIP-1alpha-R, C-C CKR-1, CC-CKR-1, RANTES-R, HM145, CCR-1, RANTES Receptor, CD191 Antigen, CMKR1, CKR1
    Associations

    News

    Trials
    22d
    The Role of CCR1 as a decisive factor for immune response activation versus suppression phenotypes in gastric cancer. (PubMed, Neoplasia)
    CCR1 modulates T cell distribution via CXCL9/CXCL10, suggesting potential therapeutic directions.
    Journal
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD68 (CD68 Molecule) • CCR1 (C-C Motif Chemokine Receptor 1)
    1m
    Epitope analysis of an anti-mouse CCR1 monoclonal antibody S15040E using flow cytometry. (PubMed, Biochem Biophys Rep)
    The results revealed that Trp176, Phe178, and Arg181 are essential amino acids for the recognition by S15040E. These results showed the involvement of the ECL2 of mCCR1 in the recognition by S15040E.
    Preclinical • Journal
    |
    CCR1 (C-C Motif Chemokine Receptor 1)
    4ms
    Commensal dysbiosis promotes the development of colorectal cancer liver Metastasis via the C-C chemokine ligand 6/C-C chemokine receptor 1 axis. (PubMed, J Cancer Res Ther)
    Commensal dysbiosis could promote CRLM development via CCL6/CCR1 signaling. Targeting this signaling axis could be an effective method to inhibit CRLM by regulating the TME.
    Journal
    |
    CCR1 (C-C Motif Chemokine Receptor 1)
    5ms
    Comprehensive analysis of the tumor immune microenvironment in gastric cancer and peritoneal metastasis based on single-cell RNA sequencing analysis. (PubMed, Sci Rep)
    scRNA-seq identified the intricate tumor immune microenvironment, highlighting the pivotal roles of TAMs and mast cells in gastric cancer peritoneal metastasis. The CCL5-CCR1 pathway emerged as a potential immune checkpoint, offering novel insights for future immunotherapeutic and targeted therapeutic strategies in the treatment of gastric cancer peritoneal metastasis.
    Journal • IO biomarker
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • S100A9 (S100 Calcium Binding Protein A9) • C1QB (Complement C1q B Chain) • CCR1 (C-C Motif Chemokine Receptor 1) • CD1C (CD1c Molecule)
    6ms
    Chemokine Receptor Profiles as Predictors of Survival and Early Progression in Follicular Lymphoma. (PubMed, EJHaem)
    Our data highlight several CRs as candidate prognostic markers and potential therapeutic targets in the context of POD24, warranting further investigation in larger, prospective cohorts. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
    Journal • IO biomarker
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CCR4 (C-C Motif Chemokine Receptor 4) • CCR7 (Chemokine (C-C motif) receptor 7) • CCR8 (C-C Motif Chemokine Receptor 8) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • CCR1 (C-C Motif Chemokine Receptor 1) • CCR3 (C-C Motif Chemokine Receptor 3) • CCR6 (C-C Motif Chemokine Receptor 6) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
    7ms
    Unlocking ESCC Progression: CCL15-CCR1 Axis Activates AKT/ERK1/2/c-Jun/CDK2 Pathway. (PubMed, J Cancer)
    In addition, we conducted a drug screening targeting CCR1 and identified Jervine as a potential CCR1 degrader. In summary, this study uncovers the relationship between CCL15-CCR1 axis and ESCC progression and provides insights into potential therapeutic strategies targeting this pathway.
    Journal
    |
    CDK2 (Cyclin-dependent kinase 2) • CCR1 (C-C Motif Chemokine Receptor 1)
    8ms
    Hyperglycemia induces an immunosuppressive microenvironment in colorectal cancer liver metastases by recruiting peripheral blood monocytes through the CCL3-CCR1 axis. (PubMed, J Immunother Cancer)
    Our study revealed complex changes in the tumor microenvironment of patients with CRLM and T2D. In particular, a novel mechanism was identified by which hyperglycemia regulates immunosuppression: the CCL3-CCR1 signaling axis. This finding offers a novel potential therapeutic target for patients with CRLM and T2D and provides an important theoretical basis for the future prediction of the prognosis of these patients.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CCL3 (C-C Motif Chemokine Ligand 3) • CCR1 (C-C Motif Chemokine Receptor 1)
    over1year
    Loss of CCL28 and CXCL17 Expression and Increase in CCR1 Expression May Be Related to Malignant Transformation of LGBLEL into Lymphoma. (PubMed, Curr Issues Mol Biol)
    The chemokine signaling pathway plays a role in the malignant transformation of LGBLEL. The decreased expression of CCL28 and CXCL17, coupled with the increased expression of CCR1, may be linked to the progression of LGBLEL into lymphoma.
    Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • CCL2 (Chemokine (C-C motif) ligand 2) • ADRB2 (Adrenoceptor Beta 2) • CCL22 (C-C Motif Chemokine Ligand 22) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • CCR1 (C-C Motif Chemokine Receptor 1)
    over1year
    Gram-negative microflora dysbiosis facilitates tumor progression and immune evasion by activating CCL3/CCL5-CCR1-MAPK-PD-L1 pathway in esophageal squamous cell carcinoma. (PubMed, Mol Cancer Res)
    Our work identifies CCR1 as a potential immune check point regulator of PD-L1 and may cause T cell exhaustion and cytotoxicity suppression in ESCC micro-environment and highlights the potential value of CCR1 as therapeutic target of immunotherapy. Implications: The esophageal microbial environment and its metabolites significantly affect the outcome of immunotherapy for ESCC.
    Journal • PD(L)-1 Biomarker • IO biomarker • Gram negative
    |
    CCL3 (C-C Motif Chemokine Ligand 3) • CCR1 (C-C Motif Chemokine Receptor 1)
    |
    PD-L1 expression
    over1year
    Oxymatrine alleviates NSAID-associated small bowel mucosal injury by regulating MIP-1/CCR1 signalling and gut microbiota. (PubMed, J Pharmacol Sci)
    MIP-1α and CCR1 were upregulated in human small bowel injury samples as compared with the normal ileal mucosa tissues. In conclusion, our findings demonstrated that OMT could alleviate NSAID-associated small bowel mucosal injury by inhibiting MIP-1γ/CCR1 signalling and regulating gut microbiota.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • CCR1 (C-C Motif Chemokine Receptor 1)
    almost2years
    Monocytes expressing activin A and CCR2 exacerbate chronic testicular inflammation by promoting immune cell infiltration. (PubMed, Hum Reprod)
    Our data indicate that macrophages are implicated in the development and progression of testicular inflammation by expressing CCR2 and activin A, which ultimately remodel the chemokine/chemokine receptor network and recruit other immune cells to the site of inflammation. Consequently, inhibition of CCR2 or activin A could serve as a potential therapeutic strategy for reducing testicular inflammation.
    Journal • Immune cell
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CCL4 (Chemokine (C-C motif) ligand 4) • CCL2 (Chemokine (C-C motif) ligand 2) • CD68 (CD68 Molecule) • CCL8 (C-C Motif Chemokine Ligand 8) • CCL3 (C-C Motif Chemokine Ligand 3) • CCR2 (C-C Motif Chemokine Receptor 2) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CCR1 (C-C Motif Chemokine Receptor 1) • CCR3 (C-C Motif Chemokine Receptor 3) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
    almost2years
    Synergistic antitumor activity by dual blockade of CCR1 and CXCR2 expressed on myeloid cells within the tumor microenvironment. (PubMed, Br J Cancer)
    Dual blockade of CCR1 and CXCR2 pathways in myeloid cells could be an effective therapy against colorectal cancer.
    Journal
    |
    CD8 (cluster of differentiation 8) • MMP2 (Matrix metallopeptidase 2) • CD31 (Platelet and endothelial cell adhesion molecule 1) • FOXP3 (Forkhead Box P3) • MMP9 (Matrix metallopeptidase 9) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • CCR1 (C-C Motif Chemokine Receptor 1)